In a preclinical comparison of the antagonist [177Lu]OPS201 (DOTA-JR11; DOTA-[Cpa-c(DCys-Aph(Hor)-DAph(Cbm)-Lys-Thr-Cys)-DTyr-NH2]) and the SST2 agonist [177Lu]DOTATATE, the antagonist showed 2.5-times higher tumor dose, longer tumor residence time, and 1.3-fold higher tumor-to-kidney dose ratio (Nicolas et al., 2017). Here, SSTR2 is linked to neoplasm.